Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 106,132

Document Document Title
WO/2015/049608A1
The present invention describes the use of propylparaben, a widely known antimicrobial, for decreasing neuronal injury induced by Status epilepticus. An objective of the invention is the administration of propylparaben immediately after ...  
WO/2015/051188A1
Probes which target diffuse and fibrillar forms of amyloid beta (Aβ) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantita...  
WO/2015/051259A1
Disclosed are compositions and methods for administering an NMDA receptor antagonist to a patient. The compositions may be administered orally, buccally, sublingually or rectally.  
WO/2015/050235A1
 The purpose of the present invention is to identify patients resistant to known HSP90 inhibitors and to provide a novel therapeutic for treating patients who have become resistant to known HSP90 inhibitors. As a means of solving this ...  
WO/2015/044251A1
The invention concerns substances for the prophylaxis and treatment of a neurodegenerative disease not based on a protein folding disorder. It further concerns substances for stabilizing photoreceptors.  
WO/2015/043567A1
The invention relates to amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of Alzheimer's dementia.  
WO/2015/044095A1
The present invention relates to compounds of general formula (I) wherein R1 is lower alkyl or lower alkyl substituted by halogen; R2, R3 are hydrogen or tritium; or to a pharmaceutically acceptable acid addition salt. The compounds may ...  
WO/2015/043398A1
Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acce...  
WO/2015/044963A9
The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a proce...  
WO/2015/043473A1
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or ph...  
WO/2015/046563A1
Without increasing the size of an existing capsule product, a further health-promoting component is sealed into the soft capsule while maintaining the DHA and EPA content of the existing product. A fish oil concentrated such that the con...  
WO/2015/046403A1
The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine deri...  
WO/2015/044952A3
Disclosed is a tramadol hydrochloride and paracetamol composition, comprising: about 2.5 to about 5 percent by weight of tramadol hydrochloride; about 25 to about 30 percent by weight of paracetamol; about 1.25 to about 1.75 percent by w...  
WO/2015/043404A1
The present invention relates to a salt of (-)-huperzine-a, which is prepared from the reaction of huperzine-a and a corresponding acid. The huperzine-a salt is selected from huperzine-a hydrochloride, hydrobromide, sulfate, phosphate, n...  
WO/2015/043511A1
Disclosed are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors, intermediates or preparation processes thereof, and pharmaceutical uses thereof, especially glucopyranosyl derivatives represent...  
WO/2015/047902A1
The present invention provides novel trimethylammonium compounds, of the Formula: (I) methods of making these compounds, methods of using the compounds for preparation of tau imaging agents, and preparation of tau imaging agent formulati...  
WO/2015/048245A1
The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of var...  
WO/2015/042706A1
The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptot...  
WO/2015/044704A1
The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.  
WO/2015/046405A1
 The purpose of the present invention is to provide a novel analgesic effective against pain, particularly nociceptive pain and neuropathic pain. The present invention provides an analgesic containing, as an active ingredient, a nipeco...  
WO/2015/042821A1
Disclosed are a compound for activating AMPK, which is an adenine and/or a pharmaceutically acceptable salt, and disclosed is a use of the compound for preventing or treating physiological conditions or diseases in mammals which can be a...  
WO/2015/044072A1
The present invention relates to indole and indazole derivatives of the following formula (I) wherein A is (AA) and the remaining variables are as defined in the specification. The compounds may be used for the treatment or prophylaxis o...  
WO/2015/044075A1
The present invention relates to compounds of formula I wherein Y is N or C-R1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with dif...  
WO/2015/043566A1
The invention relates to a peptide comprising at least one peptide which binds to an amyloid-beta species. The peptide has an amino acid sequence which is present in cyclized form. The invention also relates to the use of the peptides in...  
WO/2015/046193A1
The present invention relates to a compound represented by formula (I) (In the formula, R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, etc., X is -N(R2)-, -O- or -S-, Y...  
WO/2015/044679A1
The invention relates to the finding that turnover of DISC1 (Disrupted in schizophrenia 1) is mediated by the F-box-containing protein FBXW7 (F-box/WD repeat-containing protein 7). The sequence within DISC1 that binds to FBXW7 and target...  
WO/2015/044963A1
The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a proce...  
WO/2015/044270A1
The present invention relates to crystalline and amorphous forms of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyri dine mono-phosphate salt and methods of making these solid forms thereof. The invention compounds are modula...  
WO/2015/043111A1
The present invention relates to field of pharmaceutical chemistry, and specifically relates to a new type of benzazepine ketone derivatives (I), a preparation method therefor, and medical uses thereof. The present type of compounds can ...  
WO/2015/043522A1
The present invention relates to trifluoromethyl-containing amide alkaloid, a manufacturing method thereof, pharmaceutical combinations containing same, and pharmaceutical use thereof. The trifluoromethyl-containing amide alkaloid of the...  
WO/2015/044462A1
The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.  
WO/2015/042281A1
The present invention is based, at least in part, on the discovery that fragments of the histone deacetylase 4 (HDAC4) gene lacking the enzymatic domain promoted rod survival when electroporated into the retinas of a relevant mouse model...  
WO/2015/042580A1
Disclosed are methods of treating neuropathic pain in a human subject by administering a neublastin polypeptide at a dosage of 100-1,600 μg/kg body weight of the human subject.  
WO/2015/041544A1
This invention relates to compositions comprising bee venom and an extract of a plant of the genus Capsicum, such as Capsicum annuum, and their uses for ameliorating the symptoms of arthritis, joint pain, muscle pain, sports injury, mult...  
WO/2015/039758A1
The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compou...  
WO/2015/042243A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various diso...  
WO/2015/039619A1
Use of a traditional Chinese medicine composition in preparation of medicine for treating Alzheimer's disease (senile dementia). The traditional Chinese medicine composition is prepared from Radix Angelicae Sinensis 6.75%, Rhizoma Chuanx...  
WO/2015/039244A1
A system for obtaining and analyzing data for overall joint motion from a plurality of joints of a subject experiencing a movement disorder involves a plurality of kinematic sensors configured to be placed on a body of a subject experien...  
WO/2015/039587A1
The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in...  
WO/2015/040613A1
Provided herein are compositions, methods of use thereof and kits comprising same for prophylaxis, alleviating or treating a subject with, or experiencing symptoms associated with, attention deficit disorder/attention deficit hyperactivi...  
WO/2015/039212A1
Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or dis...  
WO/2015/040151A1
The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes p...  
WO/2015/037716A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 is an optionally substituted C1-4 alkyl, n is an integer of 1 to 4, R2 is an optionally substituted C...  
WO/2015/036972A2
Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable ...  
WO/2015/037019A3
The present invention relates to modified release compositions comprising plurality of modified release units. Particularly, the modified release units comprise at least one anti-Alzheimer's agent, at least one ion exchange resin and at ...  
WO/2015/036734A1
The present invention relates a pharmaceutical composition comprising (a) an opioid analgesic drug and/or an enkephalinase inhibitor, and (b) a selective Nav1.7 inhibitor.  
WO/2015/035500A1
Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of a...  
WO/2015/036370A1
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation...  
WO/2015/036412A1
The present invention relates to compounds of general formula (I) wherein R1 is aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from lower alkyl, halogen, lower alkyl substituted by haloge...  
WO/2015/035460A1
An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.  

Matches 401 - 450 out of 106,132